Navigation Links
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Date:4/9/2008

Phase 1 study marks the achievement of a critical milestone in our clinical development program and further supports our strategy of focusing on orally-administered, small molecule drugs with multiple mechanisms of action. Data from preclinical studies with ENMD-2076 demonstrate its significant antitumor potential as a single agent in a variety of tumor types. Through this Phase 1 study, we expect to not only determine ENMD-2076's safety profile and appropriate Phase 2 dosing schedule, but which tumor types may be better suited for this compound. We plan to initiate a second Phase 1 study in patients with hematological cancers later this year."

James S. Burns, EntreMed President & Chief Executive Officer commented, "ENMD-2076 is an exciting selective kinase inhibitor with potent single agent activity that has induced tumor regression in multiple preclinical models. ENMD-2076, developed internally, is consistent with our focus on investing behind oncology drug candidates with strong single-agent activity and with our continuing interest in selective kinase inhibitors. In parallel with the clinical trial, we will seek a pharmaceutical or biotech partner to help accelerate the development of our novel selective kinase inhibitor."

The administration of ENMD-2076 to the first patient in this important Phase 1 study will trigger a milestone payment by EntreMed pursuant to EntreMed's acquisition of Miikana Therapeutics, Inc. in January 2006. Under the terms of the merger agreement with Miikana, the dosing of the first patient triggers a $2 million payment to the former Miikana stockholders, either in cash or shares of EntreMed common stock.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. EN
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
2. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
3. EntreMed to Present at The New York Society of Security Analysts Industry Conference
4. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
5. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
6. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
7. EntreMed Raises $20 Million to Support Clinical Development Program
8. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... second quarter 2014 financial results before the NASDAQ Global ... same day, Arena will host a conference call and ... Time). The conference call may be ... for international callers. Please specify to the operator that ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, a ... compounded pharmaceuticals, announced that it is now offering ... to each individual based upon their particular genetic ... understanding the interaction between a patient,s genetics and ... very excited to provide this new service to ...
(Date:7/24/2014)... Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased by ... Reported sales increased 5% which included a 1% benefit ... as reported (EPS) were $2.49, compared with $2.24 in ... an increase of 9% over the prior-year amount of ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14
... LARGO, Fla., March 7 AlphaMed Pharmaceuticals,Corporation announced ... version of the therapeutic protein alpha 1-antitrypsin (AAT).,AlphaMed ... production system in yeast. The yeast has been ... that which is,manufactured by the human body., ...
... MOUNTAIN VIEW, Calif., March 6 Concentric Medical,Inc., the ... stroke,patients, today announced that the results of its Multi ... of the medical journal, Stroke. The,Multi MERCI trial was ... Retrieval System(TM), a "corkscrew-type" device that is delivered,into the ...
Cached Medicine Technology:AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin 2Multi Merci Trial Results Published in Peer Reviewed Journal 2
(Date:7/26/2014)... 2014 According to the Banish My ... a comprehensive guide that covers detailed instructions on how ... the need of any medication. , Vkool reveals ... and safe remedies for relieving symptoms of keratosis pilaris ...     How to treat children's keratosis pilaris ...
(Date:7/25/2014)... 26, 2014 Dental Perfection, a Derby ... services including general dentistry, clear braces and much more, ... this year in Derby. The new practice, which is ... Medical Centre in Littleover, Derby. Patients may already pre-register ... The new dental practice, which is headed by Invisalign ...
(Date:7/25/2014)... Angeles, CA (PRWEB) July 25, 2014 In ... talk about, and eager to reverse the symptoms associated with ... in the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. ... a 38-year-old father from Seattle who found himself beginning to ...
(Date:7/25/2014)... 2014 As reported by the Statesman Journal ... Heroin (7/20), police in Salem, MA as well as ... the recent heroin epidemic that has taken many lives during ... heroin-related overdose case in which police were able to make ... phone. By pretending to be the victim and claiming to ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Seniors are more ... people, a new study finds. "Almost any type ... from the age of 25 on," study co-author Randi ... a university news release. However, Martin said, this ... on processing in older adults compared with younger adults. ...
Breaking Medicine News(10 mins):Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2
... Reflex ... images and stock photos. , ... Dungannon, UK (PRWEB) March 31, 2010 -- Reflex Stock Limited, a leading provider of royalty ... of purchasing stock photos and images. , , ,The right images play a vital role ...
... ... press release summarizes several of the many content-rich video interviews now published on EHRtv.com. ... Palm Beach Gardens, FL (PRWEB) ... Health IT industry executives at HIMSS10 in Atlanta, Georgia. For those who may have missed ...
... old standby might help prevent headache from starting up, ... A drug under development could help patients with migraines, ... from developing in the first place, new research suggests. ... Lancet , examines the migraine drug telcagepant, which is ...
... ... educational organization that has certified more than 11,000 homes, has taken a look forward at ... years, Earth Advantage Institute staff has compiled a list of 8 predictions that provide an ... , ...
... ... new regulation from the Environmental Protection Agency (EPA) requires contractors that ... to be certified and follow stringent procedures to prevent lead contamination. ... EPA certification for lead-based Repair, Renovation and Painting (RRP) at all ...
... ... home, news, and food. Greenista.com,s daily emails to their reader,s inbox will keep everyone in ... New York, NY ... fashionista with a green conscience. Just in time for Earth Day’s 40th Anniversary, Greenista is ...
Cached Medicine News:Health News:Reflex Stock Limited Announces Two New Ways to Buy Stock Images and Stock Photos 2Health News:EHRtv.com Publishes Over 40 Video Interviews from HIMSS10 2Health News:EHRtv.com Publishes Over 40 Video Interviews from HIMSS10 3Health News:New Migraine Drug Might Be Safer for Some 2Health News:An Earth Day View of Green Building: Earth Advantage Institute Looks 10 Years Forward 2Health News:An Earth Day View of Green Building: Earth Advantage Institute Looks 10 Years Forward 3Health News:An Earth Day View of Green Building: Earth Advantage Institute Looks 10 Years Forward 4Health News:Window World Confirms EPA Certification under New Lead Paint Renovation Law 2Health News:Window World Confirms EPA Certification under New Lead Paint Renovation Law 3Health News:New Eco Site, Greenista.com, Launches on Earth Day 2
... MicroAire® Hi Speed Pulse Lavage is ... surfaces as well as cleansing trauma ... a great system just got better ... with the addition of attachable ...
... a complete system of surgical instruments and ... fusion surgery. The system was designed in ... research and engineering with advanced materials, techniques ... different, and because the anatomy of the ...
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... Minimally Invasive Hip Instruments are ... through a mini-incision using a ... of instruments helps reduce the ... THA by optimizing exposure and ...
Medicine Products: